

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OW nucleic - nucleic search, using sw model

Run on: August 23, 2003, 14:21:52 ; Search time 343 Seconds

(without alignments)
12222.237 Million cell updates/sec

Title: US-09-745-506-74

Perfect score: 1553
Sequence: 1 GTGATTGTTATCTGTGCT.....TCGTTTACTTAACATTCAA 1553

Scoring table: OLIGO.NUC
Gapop 60.0 , Gapext 60.0

Searched: 2552756 seqs, 1349719017 residues

Word size : 0

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database :

N.Geneseq_19Jun03:*
1: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
2: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
3: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
4: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
5: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
6: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
7: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
8: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
9: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
10: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
11: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
12: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
13: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
14: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
15: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
16: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
17: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
18: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
19: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
20: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
21: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
22: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
23: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
24: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*
25: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	1324	85.3	1574	22	AAH16397
2	1324	85.3	1739	23	ABV23243
3	1324	85.3	1739	23	ABV29087
4	1138	73.3	1696	22	AAK60866
5	1087	70.0	1554	22	AA544644
6	1053	67.8	1053	22	AAH52212
7	846	54.5	1398	22	AAH59945
8	664	42.8	1385	24	ABL60919

9	567	36.5	796	22	AAH07192	Human cDNA clone (
10	424	27.3	462	22	AAI23953	Human breast cancer
11	414	26.7	14969	22	AAK78763	Human immune/haema
12	341	22.0	1686	23	AA585172	DNA encoding novel
13	329	21.2	514	22	AAI15105	Human breast cancer
14	223	14.4	463	22	AAK63571	Human immune/haema
15	220	14.2	465	22	ABAA6423	Human breast cell
16	220	14.2	465	22	ABA57019	Human foetal liver
17	220	14.2	465	22	AAK05073	Human brain expres
18	220	14.2	465	22	AAI15235	Probe #5168 for ge
19	220	14.2	465	22	AAI04973	Probe #4964 used t
20	220	14.2	465	22	AB530297	Human liver single
21	210	13.5	249	21	AAI25260	Human secreted pro
22	208	13.4	208	22	ABA51554	Human breast cell
23	208	13.4	208	22	ABA69581	Human foetal liver
24	208	13.4	208	22	AAK17792	Human brain expres
25	208	13.4	208	22	AAI24414	Probe #14347 for g
26	208	13.4	208	22	AAI09950	Probe #9941 used t
27	208	13.4	208	22	AB543283	Human liver single
28	201	12.9	495	23	AA585169	DNA encoding novel
29	188	12.1	591	23	ABV42397	Human prostate exp
30	188	12.1	720	23	ABV22053	Human prostate exp
31	188	12.1	720	23	ABV22203	Human prostate exp
32	188	12.1	720	23	ABV27892	Human prostate exp
33	188	12.1	720	23	ABV27933	Human prostate exp
34	188	12.1	720	23	ABV28038	Human prostate exp
35	154	9.9	370	23	AA585170	DNA encoding novel
36	145	9.3	633	22	AA534287	Human cDNA encodin
37	132	8.5	513	22	AA544816	Human confly polyn
38	109	7.0	273	23	ABV35380	Human prostate exp
39	109	7.0	273	23	ABV44212	Human prostate exp
40	109	7.0	443	23	ABV14293	Human prostate exp
41	105	6.8	357	23	ABV05124	Human prostate exp
42	90	5.8	339	21	AAI17249	Human secreted pro
43	72	4.6	522	23	AA585171	DNA encoding novel
44	67	4.3	499	22	AAI23423	Human breast cancer
45	60	3.9	60	24	ABN33267	Human spliced tran

ALIGNMENTS

RESULT 1	AAH16397	standard; cDNA; 1574 BP.
ID	AAH16397	
AC	AAH16397	
XX	26-JUN-2001	(first entry)
DT	XX	
XX	Human cDNA sequence SEQ ID NO:15359.	
DE	Human cDNA sequence SEQ ID NO:15359.	
XX	Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.	
KW	Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.	
XX	Homo sapiens.	
OS	Homo sapiens.	
PN	EP1074617-A2.	
PD	07-FEB-2001.	
XX	28-JUL-2000; 2000EP-0116126.	
PF	28-JUL-2000; 2000EP-0116126.	
XX	29-JUL-1999; 99JP-0248036.	
PR	27-AUG-1999; 99JP-0300253.	
PR	11-JAN-2000; 2000JP-0118776.	
PR	02-MAY-2000; 2000JP-0183767.	
PR	09-JUN-2000; 2000JP-0241899.	
XX	(HELI-) HELIX RES INST.	
PA	Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;	
PI	Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;	
XX		

DR WPI: 2001-318749/34.
XX primer sets for synthesizing polynucleotides, particularly the 5602
PT full-length cDNAs defined in the specification, and for the detection
PT and/or diagnosis of the abnormality of the proteins encoded by the
PT full-length cDNAs -
PS Claim 8: SEQ ID 15359; 2537pp + CD ROM; English.
XX
CC The present invention describes primer sets for synthesizing 5602
CC full-length cDNAs defined in the specification. Where a primer set
CC comprises: (a) an oligo or primer and an oligonucleotide complementary
CC to the complementary strand of a polynucleotide which comprises one of
CC the 5602 nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to a 5'-end
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the combination of
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in
CC the specification. The primer sets can be used in antisense therapy and
CC in gene therapy. The primers are useful for synthesizing polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAH92446 to
CC AAH95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC represent oligonucleotides, all of which are used in the exemplification
CC of the present invention.
XX
SQ Sequence 1574 BP; 420 A; 361 C; 372 G; 421 T; 0 other;
Query Match 85.3%; Score 1324; DB 22; Length 1574;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1324; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTGATGTTATCTTGGTGTGACAGAGACACAGAGAGAGATGGCTCAAGAAATGCG 60
DB GTGATGTTATCTTGGTGTGACAGAGACACAGAGAGAGATGGCTCAAGAAATGCG 86
QY 61 CCGCCGACACAG 120
DB CCGCCGACACAG 146
QY 87 CCGCCGACACAG 146
DB CCGCCGACACAG 146
QY 121 CTGTGTCTGT 180
DB CTGTGTCTGT 206
QY 147 CTGTGTCTGT 206
DB CTGTGTCTGT 206
QY 181 TAGATGAGTCCCGACAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 240
DB TAGATGAGTCCCGACAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 266
QY 207 TAGATGAGTCCCGACAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 266
DB TAGATGAGTCCCGACAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 266
QY 241 CTTCATGATTTGAAAGGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 300
DB CTTCATGATTTGAAAGGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 326
QY 267 CTTCATGATTTGAAAGGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 326
DB CTTCATGATTTGAAAGGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 326
QY 301 TGAGAGTTGGGACATGTTGGATTACTGTGGAACCAAGCCACACATCTGTAATATAC 360
DB TGAGAGTTGGGACATGTTGGATTACTGTGGAACCAAGCCACACATCTGTAATATAC 386
QY 327 TGAGAGTTGGGACATGTTGGATTACTGTGGAACCAAGCCACACATCTGTAATATAC 386
DB TGAGAGTTGGGACATGTTGGATTACTGTGGAACCAAGCCACACATCTGTAATATAC 386
QY 361 ACTCTCTCTGACCAATGACTGAGTGAAGAGTGTGAGAGAGAGTGTGCAAAAGAGGC 420
DB ACTCTCTCTGACCAATGACTGAGTGAAGAGTGTGAGAGAGAGTGTGCAAAAGAGGC 446
QY 387 ACTCTCTCTGACCAATGACTGAGTGAAGAGTGTGAGAGAGAGTGTGCAAAAGAGGC 446
DB ACTCTCTCTGACCAATGACTGAGTGAAGAGTGTGAGAGAGAGTGTGCAAAAGAGGC 446
QY 421 AGACCTCATTTCTCTCAACATCGGCTATCTTCCGACCCATGAAGCCATTAACCTGAA 480
DB AGACCTCATTTCTCTCAACATCGGCTATCTTCCGACCCATGAAGCCATTAACCTGAA 506
QY 447 AGACCTCATTTCTCTCAACATCGGCTATCTTCCGACCCATGAAGCCATTAACCTGAA 506
DB AGACCTCATTTCTCTCAACATCGGCTATCTTCCGACCCATGAAGCCATTAACCTGAA 506
QY 481 CACATGGAAG 540
DB CACATGGAAG 566
QY 507 CACATGGAAG 566
DB CACATGGAAG 566

QY 541 TCATACAGCCTATGATGCTGCGCCGCCAGGCGCTCAACCACTGGTGGCTAAAGGCTGG 600
DB TCATACAGCCTATGATGCTGCGCCGCCAGGCGCTCAACCACTGGTGGCTAAAGGCTGG 626
QY 567 TCATACAGCCTATGATGCTGCGCCGCCAGGCGCTCAACCACTGGTGGCTAAAGGCTGG 626
DB TCATACAGCCTATGATGCTGCGCCGCCAGGCGCTCAACCACTGGTGGCTAAAGGCTGG 626
QY 601 AGCTTGATCTCCAGGCGCCCTATCATCTTCCCAAGGCTCCCAATACCTTACAGAGGAAA 660
DB AGCTTGATCTCCAGGCGCCCTATCATCTTCCCAAGGCTCCCAATACCTTACAGAGGAAA 686
QY 627 AGCTTGATCTCCAGGCGCCCTATCATCTTCCCAAGGCTCCCAATACCTTACAGAGGAAA 686
DB AGCTTGATCTCCAGGCGCCCTATCATCTTCCCAAGGCTCCCAATACCTTACAGAGGAAA 686
QY 661 CCACCGAGTGAATTCACCTTACATACACCAAGAGAGAGAGAGAGAGAGAGAGAGAGAG 720
DB CCACCGAGTGAATTCACCTTACATACACCAAGAGAGAGAGAGAGAGAGAGAGAGAGAG 746
QY 687 CCACCGAGTGAATTCACCTTACATACACCAAGAGAGAGAGAGAGAGAGAGAGAGAGAG 746
DB CCACCGAGTGAATTCACCTTACATACACCAAGAGAGAGAGAGAGAGAGAGAGAGAGAG 746
QY 721 GAAAGGATGAG 780
DB GAAAGGATGAG 806
QY 747 GAAAGGATGAG 806
DB GAAAGGATGAG 806
QY 781 AACACGATTAATCTGAATTTGATCTAGAAAGGCTTTGATGAGAGAGAGAGAGAGAG 840
DB AACACGATTAATCTGAATTTGATCTAGAAAGGCTTTGATGAGAGAGAGAGAGAGAG 866
QY 807 AACACGATTAATCTGAATTTGATCTAGAAAGGCTTTGATGAGAGAGAGAGAGAGAG 866
DB AACACGATTAATCTGAATTTGATCTAGAAAGGCTTTGATGAGAGAGAGAGAGAGAG 866
QY 841 CCGGAGACAAACATTTATCAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 900
DB CCGGAGACAAACATTTATCAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 926
QY 867 CCGGAGACAAACATTTATCAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 926
DB CCGGAGACAAACATTTATCAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 926
QY 901 AACATACGATGAATGAG 960
DB AACATACGATGAATGAG 986
QY 927 AACATACGATGAATGAG 986
DB AACATACGATGAATGAG 986
QY 961 TGATGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1020
DB TGATGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1046
QY 987 TGATGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1046
DB TGATGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1046
QY 1021 AACCTTGAGTCTTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1080
DB AACCTTGAGTCTTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1106
QY 1047 AACCTTGAGTCTTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1106
DB AACCTTGAGTCTTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1106
QY 1081 GCAGAGGAGTGAAGGCTGACCTTACCTCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1140
DB GCAGAGGAGTGAAGGCTGACCTTACCTCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1166
QY 1107 GCAGAGGAGTGAAGGCTGACCTTACCTCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1166
DB GCAGAGGAGTGAAGGCTGACCTTACCTCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1166
QY 1141 TGCTGCTTCCCAAGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1200
DB TGCTGCTTCCCAAGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1226
QY 1167 TGCTGCTTCCCAAGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1226
DB TGCTGCTTCCCAAGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1226
QY 1201 TCTTTCGACCTTGAAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1260
DB TCTTTCGACCTTGAAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1286
QY 1227 TCTTTCGACCTTGAAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1286
DB TCTTTCGACCTTGAAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1286
QY 1261 ATCAGAGACTGACAG 1320
DB ATCAGAGACTGACAG 1346
QY 1287 ATCAGAGACTGACAG 1346
DB ATCAGAGACTGACAG 1346
QY 1321 ATTC 1324
DB ATTC 1350
QY 1347 ATTC 1350
DB ATTC 1350

RESULT 2
ABV23243
ID ABV23243 standard; cDNA; 1739 BP.
XX ABV23243;
AC 16-SEP-2002 (first entry)
XX
DE Human prostate expression marker cDNA 23234.
XX
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
KW pharmacogenomic marker; gene; ss.
XX
OS Homo sapiens.
XX

PN WO200160860-A2.
XX 23-AUG-2001.
XX
XX 20-FEB-2001; 2001MO-US05171.
XX
XX 17-FEB-2000; 2000US-183319P.
PR 16-MAR-2000; 2000US-189862P.
PR 25-MAY-2000; 2000US-207454P.
PR 09-JUN-2000; 2000US-211314P.
PR 18-JUL-2000; 2000US-219007P.
PR 13-DEC-2000; 2000US-255281P.
XX
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
PI Schlegel R, Endege WO, Monahan JE;
XX WPI; 2001-662795//6.
XX
XX Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer
XX
XX Claim 1; Page 4189-4190; 11750bp; English.
XX
XX The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for:
CC (a) assessing whether a patient is afflicted with prostate cancer;
CC (b) monitoring the progression of prostate cancer in a patient;
CC (c) assessing the efficacy of a test compound to inhibit prostate
CC cancer in a patient;
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
CC in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound;
CC (g) determining whether prostate cancer has metastasized in a patient;
CC (h) assessing the aggressiveness or indolence of prostate cancer in a
CC patient;
CC (I) is also useful as a pharmacodynamic or pharmacogenomic marker.
XX
XX Sequence 1739 BP; 457 A; 389 C; 411 G; 473 T; 9 other;
SQ
Query Match 85.3%; Score 1324; DB 23; Length 1739;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1324; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTGATTGTTATCTTGGTCTGACAGAGACAGCAGAAAGAGAGATTGGGTGAGAAAACCTGC 60
DB 53 GTGATTGTTATCTTGGTCTGACAGAGACAGCAGAAAGAGAGATTGGGTGAGAAAACCTGC 112
QY 61 CCGGCGCACACAGACAGCAGCAGTAAAGTGGAGAGGGGTCGACTCAACACTTAACCTGG 120
DB 113 CCGGCGCACACAGACAGCAGCAGTAAAGTGGAGAGGGGTCGACTCAACACTTAACCTGG 172
QY 121 CTGTGTCTGTGGTCTTCTGCTGCTGAAAAGGCTGAAAGTGGCACTAAATGAGGCA 180
DB 173 CTGTGTCTGTGGTCTTCTGCTGCTGAAAAGGCTGAAAGTGGCACTAAATGAGGCA 232
QY 181 TAGATAGTCCACAGACAGTCCGGTGTGATTCCTGATCTGCAATTCTTCCCGTTC 240
DB 233 TAGATAGTCCACAGACAGTCCGGTGTGATTCCTGATCTGCAATTCTTCCCGTTC 292
QY 241 CTTTCATGATTTGAAGGCTCTCTCTCTCTCTGATGATGATCTGATCTCTCTCTCTCTG 300
DB 293 CTTTCATGATTTGAAGGCTCTCTCTCTCTCTGATGATGATCTGATCTCTCTCTCTCTG 352
QY 301 TGAGAGTTGGAGCAATGTTGATTACTGTGTGAACCAAGCCACACATCTGTAATAC 360
DB 353 TGAGAGTTGGAGCAATGTTGATTACTGTGTGAACCAAGCCACACATCTGTAATAC 412
QY 361 ACTCTTCCTGACCAATGACCTGACTGAGGAAGTGTGTGAGAGAGTGTGCTGCAAAAGAGGC 420
|||||

DB 413 ACTCTTCCTGACCAATGACCTGACTGAGGAAGTGTGTGAGAGAGTGTGCTGCAAAAGAGGC 472
QY 421 AGACCTATCTCTCCCAACCATCCGCTATCTTCCGACCATGAAAGGCAATTAACCTGGAA 480
DB 473 AGACCTATCTCTCTCCCAACCATCCGCTATCTTCCGACCATGAAAGGCAATTAACCTGGAA 532
QY 481 CACATGGAAGAGGCGCTGTGATCCGGGCTCTGGAACAAGATCGGTATCTACTCTCC 540
DB 533 CACATGGAAGAGGCGCTGTGATCCGGGCTCTGGAACAAGATCGGTATCTACTCTCC 592
QY 541 TCATACAGCTTANGATCTGCGGCCACAGGGCGTCAACACTGTTGGCTAAAGGCTTGG 600
DB 593 TCATACAGCTTANGATCTGCGGCCACAGGGCGTCAACACTGTTGGCTAAAGGCTTGG 652
QY 601 AGCTTGACTCTCCAGGCGCATACATCTCTTCCAAAGCTCCCACTACCTCTACAGGGAAA 660
DB 653 AGCTTGACTCTCCAGGCGCATACATCTCTTCCAAAGCTCCCACTACCTCTACAGGGAAA 712
QY 661 CCACGAGTGAATTAACGTTAACTACACCCCAAGACCTGAGCAAAAGTCAATGCTGCAGT 720
DB 713 CCACGAGTGAATTAACGTTAACTACACCCCAAGACCTGAGCAAAAGTCAATGCTGCAGT 772
QY 721 GAAAGGAATTGACGGTGTCTGTCACTCTTTTCTGTAAGACTGTATAGAGACA 780
DB 773 GAAAGGAATTGACGGTGTCTGTCACTCTTTTCTGTAAGACTGTATAGAGACA 832
QY 781 AACACGATTAATCTGAATGTACTCAAGAGCTTTATGACAGGTGTAGATTTCTTTC 840
DB 833 AACACGATTAATCTGAATGTACTCAAGAGCTTTATGACAGGTGTAGATTTCTTTC 892
QY 841 CCGGAACAACAACTTATCAAGAAAGAGGAAATCTGCACTGAGAAAGCTTGTCTCT 900
DB 893 CCGGAACAACAACTTATCAAGAAAGAGGAAATCTGCACTGAGAAAGCTTGTCTCT 952
QY 901 ACATCTGGAATGGAGGCTTATGACACTGTAGTAATCTGTCTCTGCAACCATGAT 960
DB 953 ACATCTGGAATGGAGGCTTATGACACTGTAGTAATCTGTCTCTGCAACCATGAT 1012
QY 961 TGATCGAATTAAGAAACACTTAACCTATCTCATATTCGCTTACCTTGGGGTGGGAG 1020
DB 1013 TGATCGAATTAAGAAACACTTAACCTATCTCATATTCGCTTACCTTGGGGTGGGAG 1072
QY 1021 AACCTTGAAGTCTCAAGTCAAAAGTGTGGCCCTGTGTCTGTCTGTGGAGACGCTTCT 1080
DB 1073 AACCTTGAAGTCTCAAGTCAAAAGTGTGGCCCTGTGTCTGTGTGGAGACGCTTCT 1132
QY 1081 GCAGGGTGTGAGGCTGACCTTTACCTCACAGGTGAGATGTCCTCATCATGATCTTGA 1140
DB 1133 GCAGGGTGTGAGGCTGACCTTTACCTCACAGGTGAGATGTCCTCATCATGATCTTGA 1192
QY 1141 TGGCTGCTCCCAAGGAATTAATGATCATCTCTGTGGAACACAGCAACCTGAAGGCTT 1200
DB 1193 TGGCTGCTCCCAAGGAATTAATGATCATCTCTGTGGAACACAGCAACCTGAAGGCTT 1252
QY 1201 TCTTTTGAAGCTTCAAGATATGCTGATTTCTCACTTGGAGAAATTAATATTAATCTT 1260
DB 1253 TCTTTTGAAGCTTCAAGATATGCTGATTTCTCACTTGGAGAAATTAATATTAATCTT 1312
QY 1261 ATCAGAGACTGACAGGAGCCCTTTCAGGTGTATTAATTCAGAAACATCAGAGTAACAC 1320
DB 1313 ATCAGAGACTGACAGGAGCCCTTTCAGGTGTATTAATTCAGAAACATCAGAGTAACAC 1372
QY 1321 ATTTC 1324
DB 1373 ATTTC 1376
RESULT 3
ABV29087
ID ABV29087 standard; cDNA; 1739 BP.
XX
XX ABV29087;
XX

DT	16-SEP-2002 (first entry)	
DE	Human prostate expression marker CDNA 29078.	
XX		
KW	Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;	
KM	pharmacogenomic marker; gene; sg.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200160860-A2.	
PD	23-AUG-2001.	
XX		
PF	20-FEB-2001; 2001WO-US05171.	
XX		
PR	17-FEB-2000; 2000US-183319P.	
PR	16-MAR-2000; 2000US-189862P.	
PR	25-MAY-2000; 2000US-207454P.	
PR	09-JUN-2000; 2000US-211314P.	
PR	18-JUL-2000; 2000US-219007P.	
PR	13-DEC-2000; 2000US-255281P.	
XX		
PA	(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.	
PI	Schlegel R, Endege WO, Monahan JE;	
XX		
DR	WPI: 2001-662795/76.	
XX		
PT	Novel isolated nucleic acid molecule associated with cancerous state of	
PT	prostate cells and correlating with presence of prostate cancer, useful	
PT	for detecting presence of prostate cancer, stage of prostate cancer -	
PS	Claim 1; Page 6170; 11750pp; English.	
XX		
CC	The invention relates to an isolated nucleic acid molecule (I) comprising	
CC	a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the	
CC	specification or its complement. (I) is useful for:	
CC	(a) assessing whether a patient is afflicted with prostate cancer;	
CC	(b) monitoring the progression of prostate cancer in a patient;	
CC	(c) assessing the efficacy of a test compound to inhibit prostate	
CC	cancer in a patient;	
CC	(d) assessing the efficacy of a therapy for inhibiting prostate cancer	
CC	in a patient;	
CC	(e) selecting a composition for inhibiting prostate cancer in a patient;	
CC	(f) assessing the prostate cell carcinogenic potential of a compound;	
CC	(g) determining whether prostate cancer has metastasized in a patient;	
CC	(h) assessing the aggressiveness or indolence of prostate cancer in a	
CC	patient;	
CC	(I) is also useful as a pharmacodynamic or pharmacogenomic marker.	
XX		
XX		
SQ	Sequence 1739 BP; 457 A; 389 C; 411 G; 473 T; 9 other;	
XX		
Query Match	85.3%; Score 1324; DB 23; Length 1739;	
Best Local Similarity	100.0%; Pred. No. 0;	
Matches 1324; Conservative	0; Mismatches 0; Indels 0; Gaps 0	
0Y	1 GTGATTGTTATCTTGGTGTGCTGCAGAGACGACGAGAGAGAGATTGGGTACAGAAAATCGC 60	
Db	53 GTGATTGTTATCTTGGTGTGCTGCAGAGACGACGAGAGAGAGATTGGGTACAGAAAATCGC 112	
0Y	61 CCTGGCCGACACAGACACAGCCACTAGTGGGACAGAGGGTCTCTGACTCAGACTTAACCTGG 120	
Db	113 CCTGGCCGACACAGACACAGCCACTAGTGGGACAGAGGGTCTCTGACTCAGACTTAACCTGG 172	
0Y	121 CTGTTCTCGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 180	
Db	173 CTGTTCTCGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 232	
0Y	181 TAGATGATCCCGACAGACAGTCCGGTTGTAGATTCCCTGATCTGCATTTCTCCCGTTTC 240	
Db	233 TAGATGATCCCGACAGACAGTCCGGTTGTAGATTCCCGATCTGCATTTCTCCCGTTTC 292	
0Y	241 CTTCACTGATTTGGAAGGCTCTCTTCTTCTTCTTGAATGACTTTCATCCCTCTCGTTTGC 300	

Db		293	CTTCATGGAATTGAAAGCGTCTCCTTTCTCTCCTTAATGACTTGTCATCCCTCTGTTTTGC	352
OY		301	TGAGAGTTGGACAAATGTGGATTACTGTGTGAACAACGCCACCACATACTGTAATAC	360
Db		353	TGAGAGTTGGACAAATGTGGATTACTGTGTGAACAACGCCACCACATACTGTAATAC	412
OY		361	ACCTTTCCTGACCAATACCTGCAATGTGAGGAAGCATGTGAGAGAGGTGCGCAAAAAGAACGC	420
Db		413	ACTTCTTCCTGACCAATACCTGCAATGTGAGGAAGCATGTGAGAGAGGTGCGCAAAAAGAACGC	472
OY		421	AGACCTCATTCCTCTACCATCCGCGCTATCTTCGACCCATVGAAAGGCATAACTGGA	480
Db		473	AGACCTCATTCCTCTACCATCCGCGCTATCTTCGACCCATVGAAAGGCATAACTGGA	532
OY		481	CACATVGAAGAAGCGCGCTGTGATCCGGGCTCTGGAAGACAGAGTCGGTATCTACTGCC	540
Db		533	CACATVGAAGAAGCGCGCTGTGATCCGGGCTCTGGAAGACAGAGTCGGTATCTACTGCC	592
OY		541	TCATACAGCCCTATATGCTGCGCCCCAAGGGGTCACAACTGCTTGGCTTAAGGGCGTTGG	600
Db		593	TCATACAGCCCTATATGCTGCGCCCCAAGGGGTCACAACTGCTTGGCTTAAGGGCGTTGG	652
OY		601	AGCTTGAACCTCCAGGCCCATPACATCCCTCCAAAGCTCCCAACTACCTACAGAGGAAA	660
Db		653	AGCTTGAACCTCCAGGCCCATPACATCCCTCCAAAGCTCCCAACTACCTACAGAGGAAA	712
OY		661	CCACCGAGTAGAATTCACAGTTAACTACACCCAAGACCTGGACAAAGTCATGTCTGCAGT	720
Db		713	CCACCGAGTAGAATTCACAGTTAACTACACCCAAGACCTGGACAAAGTCATGTCTGCAGT	772
OY		721	GAAAGGAATTGACGGTGTCTGTGCACCTCTTTTCTGCTAGAGAGCTGGTATGAGGAACA	780
Db		773	GAAAGGAATTGACGGTGTCTGTGCACCTCTTTTCTGCTAGAGAGCTGGTATGAGGAACA	832
OY		781	AACACGGATTATGTGAATTGTACTGCAGAAAGCCTTGATGAGAGTGGATGATTTCTCTTC	840
Db		833	AACACGGATTATGTGAATTGTACTGCAGAAAGCCTTGATGAGAGTGGATGATTTCTCTTC	892
OY		841	CCGGACAAACAACTTATATCAGAAAGAGGAAATTCGTCACTGGAGAAAGCCTTTGCTTCT	900
Db		893	CCGGACAAACAACTTATATCAGAAAGAGGAAATTCGTCACTGGAGAAAGCCTTTGCTTCT	952
OY		901	ACATACGTGGAATGGAGCGGTTATGACACACTGGAATGAATCTCTCCCTGGCAACCATGAT	960
Db		953	ACATACGTGGAATGGAGCGGTTATGACACACTGGAATGAATCTCTCCCTGGCAACCATGAT	1012
OY		961	TGATCGAATAAAAAGACACTAAAACTATCTCATATTGCGTTAGCCCTTGGGGTGGGAG	1020
Db		1013	TGATCGAATAAAAAGACACTAAAACTATCTCATATTGCGTTAGCCCTTGGGGTGGGAG	1072
OY		1021	AACCTTGAAGTCTCAAGTCAAAGTCTGTGGCCCTGTGCTGCTTCTGGGACAGCGTCT	1080
Db		1073	AACCTTGAAGTCTCAAGTCAAAGTCTGTGGCCCTGTGCTGCTTCTGGGACAGCGTCT	1132
OY		1081	GCAGGGTGTGAGCGTGCACCTTATACCTCACAGGTGAGATGTCCATCATGATPACTTTGGA	1140
Db		1133	GCAGGGTGTGAGCGTGCACCTTATACCTCACAGGTGAGATGTCCATCATGATPACTTTGGA	1192
OY		1141	TGCGTCTTCCCAGGAATAAATGTGATCCTGTGGAACACAGCAACATGSAACGAGGCTT	1200
Db		1193	TGCGTCTTCCCAGGAATAAATGTGATCCTGTGGAACACAGCAACATGSAACGAGGCTT	1253
OY		1201	TCCTTTCGACCTTGAGATATGCGAGATTCTCACTGGAGAAATAGATAAATATATATCTCT	1260
Db		1253	TCCTTTCGACCTTGAGATATGCGAGATTCTCACTGGAGAAATAGATAAATATATATCTCT	1312
OY		1261	ATCAGAGACTGACAGGGAACCTCTTCAGGTGTATTAATTGCAGAAACATCAGATPAACAC	1320
Db		1313	ATCAGAGACTGACAGGGAACCTCTTCAGGTGTGTAAATTGCAGAAACATCAGATPAACAC	1372
OY		1321	ATTC 1324	

Db 1373 ATTC 1376

RESULT 4

ID AAK60866 standard; cDNA; 1696 BP.

XX AAK60866;

XX 06-NOV-2001 (first entry)

DE Human Immune/haematopoietic antigen encoding cDNA SEQ ID NO:5926.

XX Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;

KW cytostatic; gene therapy; vaccine; metastasis; ss.

XX Homo sapiens.

OS

PN W0200157182-A2.

XX

PD 09-AUG-2001.

XX

PF 17-JAN-2001; 2001WO-US01354.

XX

PR 31-JAN-2000; 2000US-0179065.

PR 04-FEB-2000; 2000US-0180628.

PR 24-FEB-2000; 2000US-0184664.

PR 02-MAR-2000; 2000US-0186350.

PR 16-MAR-2000; 2000US-0189874.

PR 17-MAR-2000; 2000US-0190076.

PR 18-APR-2000; 2000US-0198123.

PR 19-MAY-2000; 2000US-0205515.

PR 07-JUN-2000; 2000US-0209467.

PR 28-JUN-2000; 2000US-0214886.

PR 30-JUN-2000; 2000US-0215135.

PR 07-JUL-2000; 2000US-0216647.

PR 07-JUL-2000; 2000US-0216880.

PR 11-JUL-2000; 2000US-0217487.

PR 11-JUL-2000; 2000US-0217496.

PR 14-JUL-2000; 2000US-0218290.

PR 26-JUL-2000; 2000US-0220963.

PR 26-JUL-2000; 2000US-0220964.

PR 14-AUG-2000; 2000US-0224518.

PR 14-AUG-2000; 2000US-0224519.

PR 14-AUG-2000; 2000US-0225213.

PR 14-AUG-2000; 2000US-0225214.

PR 14-AUG-2000; 2000US-0225266.

PR 14-AUG-2000; 2000US-0225267.

PR 14-AUG-2000; 2000US-0225268.

PR 14-AUG-2000; 2000US-0225270.

PR 14-AUG-2000; 2000US-0225447.

PR 14-AUG-2000; 2000US-0225757.

PR 14-AUG-2000; 2000US-0225758.

PR 14-AUG-2000; 2000US-0225759.

PR 18-AUG-2000; 2000US-0226279.

PR 22-AUG-2000; 2000US-0226681.

PR 22-AUG-2000; 2000US-0226686.

PR 22-AUG-2000; 2000US-0227182.

PR 23-AUG-2000; 2000US-0227009.

PR 30-AUG-2000; 2000US-0228924.

PR 01-SEP-2000; 2000US-0229287.

PR 01-SEP-2000; 2000US-0229343.

PR 01-SEP-2000; 2000US-0229344.

PR 01-SEP-2000; 2000US-0229345.

PR 05-SEP-2000; 2000US-0229509.

PR 05-SEP-2000; 2000US-0229513.

PR 06-SEP-2000; 2000US-0230437.

PR 06-SEP-2000; 2000US-0230438.

PR 08-SEP-2000; 2000US-0231242.

PR 08-SEP-2000; 2000US-0231243.

PR 08-SEP-2000; 2000US-0231244.

PR 08-SEP-2000; 2000US-0231413.

PR 08-SEP-2000; 2000US-0231414.

PR 08-SEP-2000; 2000US-0232080.

PR 08-SEP-2000; 2000US-0232081.

PR 12-SEP-2000; 2000US-0231968.

PR 14-SEP-2000; 2000US-0232397.

PR 14-SEP-2000; 2000US-0232398.

PR 14-SEP-2000; 2000US-0232399.

PR 14-SEP-2000; 2000US-0232400.

PR 14-SEP-2000; 2000US-0232401.

PR 14-SEP-2000; 2000US-0233063.

PR 14-SEP-2000; 2000US-0233064.

PR 14-SEP-2000; 2000US-0233065.

PR 21-SEP-2000; 2000US-0234223.

PR 21-SEP-2000; 2000US-0234224.

PR 25-SEP-2000; 2000US-0234997.

PR 25-SEP-2000; 2000US-0234998.

PR 26-SEP-2000; 2000US-0235484.

PR 27-SEP-2000; 2000US-0235834.

PR 27-SEP-2000; 2000US-0235836.

PR 29-SEP-2000; 2000US-0236367.

PR 29-SEP-2000; 2000US-0236368.

PR 29-SEP-2000; 2000US-0236369.

PR 29-SEP-2000; 2000US-0236370.

PR 02-OCT-2000; 2000US-0236802.

PR 02-OCT-2000; 2000US-0237037.

PR 02-OCT-2000; 2000US-0237038.

PR 02-OCT-2000; 2000US-0237039.

PR 02-OCT-2000; 2000US-0237040.

PR 13-OCT-2000; 2000US-0239935.

PR 13-OCT-2000; 2000US-0239937.

PR 20-OCT-2000; 2000US-0240960.

PR 20-OCT-2000; 2000US-0241221.

PR 20-OCT-2000; 2000US-0241785.

PR 20-OCT-2000; 2000US-0241786.

PR 20-OCT-2000; 2000US-0241787.

PR 20-OCT-2000; 2000US-0241808.

PR 20-OCT-2000; 2000US-0241809.

PR 20-OCT-2000; 2000US-0241826.

PR 01-NOV-2000; 2000US-0244617.

PR 08-NOV-2000; 2000US-0246474.

PR 08-NOV-2000; 2000US-0246475.

PR 08-NOV-2000; 2000US-0246476.

PR 08-NOV-2000; 2000US-0246477.

PR 08-NOV-2000; 2000US-0246478.

PR 08-NOV-2000; 2000US-0246523.

PR 08-NOV-2000; 2000US-0246524.

PR 08-NOV-2000; 2000US-0246525.

PR 08-NOV-2000; 2000US-0246526.

PR 08-NOV-2000; 2000US-0246527.

PR 08-NOV-2000; 2000US-0246528.

PR 08-NOV-2000; 2000US-0246532.

PR 08-NOV-2000; 2000US-0246609.

PR 08-NOV-2000; 2000US-0246610.

PR 08-NOV-2000; 2000US-0246611.

PR 08-NOV-2000; 2000US-0246613.

PR 17-NOV-2000; 2000US-0249207.

PR 17-NOV-2000; 2000US-0249208.

PR 17-NOV-2000; 2000US-0249209.

PR 17-NOV-2000; 2000US-0249210.

PR 17-NOV-2000; 2000US-0249211.

PR 17-NOV-2000; 2000US-0249212.

PR 17-NOV-2000; 2000US-0249213.

PR 17-NOV-2000; 2000US-0249214.

PR 17-NOV-2000; 2000US-0249215.

PR 17-NOV-2000; 2000US-0249216.

PR 17-NOV-2000; 2000US-0249217.

PR 17-NOV-2000; 2000US-0249218.

PR 17-NOV-2000; 2000US-0249244.

PR 17-NOV-2000; 2000US-0249245.

PR 17-NOV-2000; 2000US-0249264.

PR 17-NOV-2000; 2000US-0249265.

PR 17-NOV-2000; 2000US-0249267.

PR 17-NOV-2000; 2000US-0249297.

PR 17-NOV-2000; 2000US-0249299.

PR	17-NOV-2000;	2000US-0249300.
PR	01-DEC-2000;	2000US-0250160.
PR	01-DEC-2000;	2000US-0250391.
PR	05-DEC-2000;	2000US-0251030.
PR	05-DEC-2000;	2000US-0251988.
PR	05-DEC-2000;	2000US-0256719.
PR	06-DEC-2000;	2000US-0254719.
PR	08-DEC-2000;	2000US-0251856.
PR	08-DEC-2000;	2000US-0251868.
PR	08-DEC-2000;	2000US-0251869.
PR	08-DEC-2000;	2000US-0251990.
PR	11-DEC-2000;	2000US-0254097.
PR	05-JAN-2001;	2001US-0235678.
PA	(HUMA-) HUMAN GENOME SCI INC.	
PI	Rosen CA, Barash SC, Ruben SM;	
XX	WPI: 2001-483426/52.	
DR	P-PSDB; AAM88085.	
XX		
PT	Nucleic acids encoding human immune/hematopoietic antigen polypeptides,	
PT	useful for preventing, diagnosing and/or treating cancers and	
PT	metastasis -	
XX		
PS	Claim 1; SEQ ID NO 5926; 3071pp + Sequence Listing; English.	
XX		
CC	AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)	
CC	amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic	
CC	activity, and can be used in gene therapy and vaccine production. (I)	
CC	proteins and polynucleotides may be used in the prevention, diagnosis and	
CC	treatment of diseases associated with inappropriate (I) expression. For	
CC	example, they may be used to treat disorders associated with decreased	
CC	expression by rectifying mutations or deletions in a patient's genome	
CC	that affect the activity of (I) by expressing inactive proteins or to	
CC	supplement the patient's own production of (I). Additionally, (I)	
CC	polynucleotides may be used to produce the secreted (I), by inserting the	
CC	nucleic acids into a host cell and culturing the cell to express the	
CC	protein. (I) proteins and polynucleotides may be used to prevent,	
CC	diagnose and treat immune/hematopoietic-related diseases, especially	
CC	cancers and cancer metastases of hematopoietic-derived cells. AAK64703	
CC	to AAK7694 represent human immune/hematopoietic antigen genomic	
CC	sequences from the present invention. AAK54942 to AAK54950 and AAM82169	
CC	represent sequences used in the exemplification of the present invention.	
XX		
SQ	Sequence 1696 BP; 510 A; 369 C; 379 G; 435 T; 3 other;	
	Query Match	73.3%; Score 1138; DB 22; Length 1696;
	Best Local Similarity	100.0%; Pred. No. 0;
	Matches 1138; Conservative	0; Mismatches 0; Indels 0; Gaps 0
OY	187 AGTCCCGACGACAGCGCGTTTGATGATCCCTGATGTCATATTCCTCCCTTCAT	246
DB	249 AGTCCCGACGACAGCGCGTTTGATGATCCCTGATGTCATATTCCTCCCTTCAT	308
OY	247 GGAATTGAAGGCTCTCTTCTTCCTTGATGATCTTGGATCCCTCGTTGCTGAGAG	306
DB	309 GGAATTGAAGGCTCTCTTCTTCCTTGATGATCTTGGATCCCTCGTTGCTGAGAG	368
OY	307 TTGGGACAAATGTGGATTACTGCTGGAACCAAGCCACACATCTGTAATTAACACTCTT	366
DB	369 TTGGGACAAATGTGGATTACTGCTGGAACCAAGCCACACATCTGTAATTAACACTCTT	428
OY	367 CCTGACCAATGACCGGACGTGAGGAGTGTGGAAGGAGTGCGCAAAAGGACGACCT	426
DB	429 CCTGACCAATGACCGGACGTGAGGAGTGTGGAAGGAGTGCGCAAAAGGACGACCT	488
OY	427 CATTCCTCTACCAATCGGCTATCTTCGACCAATGAAGCCATTAACCTGGAACACATG	486
DB	489 CATTCCTCTACCAATCGGCTATCTTCGACCAATGAAGCCATTAACCTGGAACACATG	548
OY	487 GAAGGAGCGCCCTGGATTCGCGGCTCTGGAGAACAGAGTGGATTAATCTTCTCTCATAC	546

Db	549	GAAGAGCGCCCTGGTGTATCCGGGCTTGGAGAAACAGTGGTATCTCTCTCATAC	608
QY	547	AGCCTATGATGCTGCGCCCGCAGGGCGTCAAACACTGGTTGGCTAAAGGGCTTGGAGCTTG	606
Db	609	AGCCTATGATGCTGCGCCCGCAGGGCGTCAAACAACTGGTTGGCTAAAGGGCTTGGAGCTTG	668
QY	607	TACCTCCAGGCCCATACATCTCTTCCAAAGCTCCCAACTACCTACAGAGGGAAACACACG	666
Db	669	TACCTCCAGGCCCATACATCTCTTCCAAAGCTCCCAACTACCTACAGAGGGAAACACACG	728
QY	667	AGTGAAATTAAGGTTAACTACACCCCAAGACCTGGGCAAAAGTCAAGTCTGGCAGTGAAGG	726
Db	729	AGTGAAATTAAGGTTAACTACACCCCAAGACCTGGGCAAAAGTCAAGTCTGGCAGTGAAGG	788
QY	727	AATTGAGCGGTTTCTGTCTCACTCTTTTCTGTCTGAGACTGGTAAATGAGAAACAAACAG	786
Db	789	AATTGAGCGGTTTCTGTCTCACTCTTTTCTGTCTGAGACTGGTAAATGAGAAACAAACAG	848
QY	787	GATTAAATCGAATTTGATCTCAGAAAGGCTTGTATGCAGTGGTAGATTTTCTTCCCGGAA	846
Db	849	GATTAAATCGAATTTGATCTCAGAAAGGCTTGTATGCAGTGGTAGATTTTCTTCCCGGAA	908
QY	847	CAAAACACTTTATTCAGAAAGCGAAATTTCTGTCACTGGAGAGACCTTTGGCTTCACATAC	906
Db	909	CAAAACACTTTATTCAGAAAGCGAAATTTCTGTCACTGGAGAGACCTTTGGCTTCACATAC	968
QY	907	TGGAATGGAGCGGTTATGACACATGSGATGAATCTGTCCCGGCAACCATGATTTGATCG	966
Db	969	TGGAATGGAGCGGTTATGACACATGSGATGAATCTGTCCCGGCAACCATGATTTGATCG	1028
QY	967	AATTAATAAGACACCTAAACACTATCTCATATTCGCTTAAAGCCTTGGGGTGGGGAGAACCTT	1026
Db	1029	AATTAATAAGACACCTAAACACTATCTCATATTCGCTTAAAGCCTTGGGGTGGGGAGAACCTT	1088
QY	1027	AGACTCTCAGTCAAAAGTCGTGGCCCTGTGCTGTCTGTGGAGACAGCGTTTCGCAAGG	1086
Db	1089	AGACTCTCAGTCAAAAGTCGTGGCCCTGTGCTGTCTGTGGAGACAGCGTTTCGCAAGG	1148
QY	1087	TGTTGAGGCGTACGCTTTTACCTCACAAGTGAAGTGTCCATCAATGATTTTGGATGTCTGC	1146
Db	1149	TGTTGAGGCGTACGCTTTTACCTCACAAGTGAAGTGTCCATCAATGATTTTGGATGTCTGC	1208
QY	1147	TTTCCCAAGAATAAATGTATCTCTCTGTGTGAACACAGCACTGAACAGGCTTCTTTC	1206
Db	1209	TTTCCCAAGAATAAATGTATCTCTCTGTGTGAACACAGCACTGAACAGGCTTCTTTC	1268
QY	1207	TGACCTTCGAGATATGCTGGATTTCTCACTTGGAGAAATTAATTAATTAATCTATCGA	1266
Db	1269	TGACCTTCGAGATATGCTGGATTTCTCACTTGGAGAAATTAATTAATTAATCTATCGA	1330
QY	1267	GACTGACAGGAGACCTTCTTCAGGTGGTATTAATTTGCAAAACATCAAGATTAACATATTC	1324
Db	1329	GACTGACAGGAGACCTTCTTCAGGTGGTATTAATTTGCAAAACATCAAGATTAACATATTC	1386

KW antibacterial; immunosuppressive; vasotropic; antiparkinsonian;
KW neuroprotective; osteopathic; antidiabetic; antiallergic;
KW immunostimulant; analgesic; gene therapy.
XX
XX Homo sapiens.
XX MO200164834-A2.
XX PD 07-SEP-2001.
XX 26-FEB-2001; 2001WO-US04926.
XX 28-FEB-2000; 2000US-0515126.
XX 18-MAY-2000; 2000US-0577409.
XX 17-JUN-2000; 2000US-0597707.
XX 14-JUL-2000; 2000US-0616807.
XX 19-SEP-2000; 2000US-0664641.
XX (HYSE-) HYSEQ INC.
XX Tang Y.T., Liu C., Zhou P., Asundi V., Zhang J., Zhao Q.A., Fan F.,
PI Xue A.J., Yang Y., Wehrman T., Wang J., Ma Y., Wang D., Chen R., Xu C.;
PI Dmanac R.;
XX WPI: 2001-589862/66.
XX P-PSDB; AAU27744.
XX Novel polypeptides and nucleic acids obtained from cDNA libraries
PT prepared from various human tissues, for diagnosis, treatment of
PT cancer, neurological, inflammatory disorders and for use in arrays for
PT detection -
XX
XX Claim 1; SEQ ID No 69; 153pp; English.
XX
XX Sequences AA544576-AA544919 represent full-length polynucleotides and
XX and contig polynucleotides encoding polypeptides of the invention. The DNA
XX and protein sequences are useful for the treatment, diagnosis and
XX prevention of various types of disorder in a mammalian subject such as a
XX human, dog, monkey, mouse, hamster or rat. The disorders include cancers
XX such as leukemia, lymphoma and neuroblastoma, autoimmune disorders such
XX as multiple sclerosis, connective tissue disease, rheumatoid arthritis,
XX diabetes mellitus, allergic rhinitis, asthma and eczema, nervous system
XX disorders such as Parkinson's disease, Alzheimer's disease, Huntington's
XX chorea, amyotrophic lateral sclerosis, spinal muscular atrophy and
XX Menckie disease, inflammatory disorders such as nephritis. Crohn's
XX disease, ischemia-reperfusion injury, shock, sepsis and inflammatory
XX bowel disease. The sequences exhibit activity relating to angiogenesis,
XX cell proliferation, cell differentiation, stem cell growth factor,
XX activin or inhibin. Therefore, they can be used to manipulate stem cells
XX in culture to give rise to neuroepithelial cells that can be used to
XX augment or replace cells damaged by illness, accidental damage or genetic
XX disorders. The sequences may also be used for regeneration of bone,
XX cartilage, tendons and ligaments and in tissue repair and burn healing.
XX Note: Some sequences for this patent did not form part of the printed
XX specification, but were obtained in electronic format directly from WIFO
XX at ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 1554 BP: 428 A; 358 C; 346 G; 422 T; 0 other:
SO
Query Match 70.0%; Score 1087; DB 22; Length 1554;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 1137; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DB 298 TTGGACAAATGTGGATTACTGTGTGAGCAAGCCACCACATACTGTAATAATACACTCTT 357
QY 367 CCTGACCAATGACCTGACTGAGAGAAATGATGAGAGAGTGTCTGCAAAAAGAGGAGACT 426
DB 358 CCTGACCAATGACCTGACTGAGAGAAATGATGAGAGAGTGTCTGCAAAAAGAGGAGACT 417
QY 427 CATTCCTGCTACCACTCCGCTATCTTCCGAGCCATGAGAGGAGCATTAACCTGGAACATG 486
DB 418 CATTCCTGCTACCACTCCGCTATCTTCCGAGCCATGAGAGGAGCATTAACCTGGAACATG 477
QY 487 GAAGAGGAGCCTGTGTATCCGGCTCTGAGAGAAAGAGTGGTATCTACTCTCTCATAC 546
DB 478 GAAGAGGAGCCTGTGTATCCGGCTCTGAGAGAAAGAGTGGTATCTACTCTCTCATAC 537
QY 547 AGCCATATATCTGTGGCCCAAGGGGTGAACAACCTGTGTGTAAGAGGCTTGAGCTTG 606
DB 538 AGCCATATATGTGTGGCCCAAGGGGTGAACAACCTGTGTGTAAGAGGCTTGAGCTTG 597
QY 607 TACCTCCAGGCCATACATCTCTTCCAAAGCTCCCAACTACCTTACAGAGAGGAAACACCG 666
DB 598 TACCTCCAGGCCATACATCTCTTCCAAAGCTCCCAACTACCTTACAGAGAGGAAACACCG 657
QY 667 AGTAGAATTCACAGTTAACTACACCCAAAGCCTGGACAAAGTCAATGTCTGCACTGAAAG 726
DB 658 AGTAGAATTCACAGTTAACTACACCCAAAGCCTGGACAAAGTCAATGTCTGCACTGAAAG 717
QY 727 AATTGACGCTGTCTGTACACTCTCTTTCTGCTGAGACTGGTATGAGGAACAACACG 786
DB 718 AATTGACGCTGTCTGTACACTCTCTTTCTGCTGAGACTGGTATGAGGAACAACACG 777
QY 787 GATTATATCGAATTTACTACAGAAAGCTTTGATGAGAGTGTCTCTTCCCGGA 846
DB 778 GATTATATCGAATTTACTACAGAAAGCTTTGATGAGAGTGTCTCTTCCCGGA 837
QY 847 CAACACCTTTATTCAGAAAGAGGAAATTCCTGCTACTGAGAAAGCTTTCTTCATAC 906
DB 838 CAACACCTTTATTCAGAAAGAGGAAATTCCTGCTACTGAGAAAGCTTTCTTCATAC 897
QY 907 TGGAAATGGAGGCTTATGACACCTGAGAAATTCCTGCTGAGAAAGCTTTCTTCATAC 966
DB 898 TGGAAATGGAGGCTTATGACACCTGAGAAATTCCTGCTGAGAAAGCTTTCTTCATAC 957
QY 967 AATAAAGAGACACTTAAACATTCATATTCCTTACCTTACCTTGGGGTGGAGAACTT 1026
DB 958 AATAAAGAGACACTTAAACATTCATATTCCTTACCTTGGGGTGGAGAACTT 1017
QY 1027 AGAGTCTCAAGTCAAGTCTGAGGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1086
DB 1018 AGAGTCTCAAGTCAAGTCTGAGGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1077
QY 1087 TGTGAGGCTGACCTTACCTACAGAGGAGATGCCATGATGATGATGATGATGATGATGATG 1146
DB 1078 TGTGAGGCTGACCTTACCTACAGAGGAGATGCCATGATGATGATGATGATGATGATGATG 1137
QY 1147 TTCCCAAGAAATTAATGTCATCTCTGTAACACAGCAACACTGAGAGGCTTCTTTC 1206
DB 1138 TTCCCAAGAAATTAATGTCATCTCTGTAACACAGCAACACTGAGAGGCTTCTTTC 1197
QY 1207 TGACCTTGAGATATGCTGATGATCTCACTTGGAGATTAAGATTAATTAATCTATCTATCAG 1266
DB 1198 TGACCTTGAGATATGCTGATGATCTCACTTGGAGATTAAGATTAATTAATCTATCTATCAG 1257
QY 1267 GACTTACAGAGGAGCCTTTCAGGCTGTATTAATTCAGAAACATCAGAGTATACACTTC 1324
DB 1258 GACTTACAGAGGAGCCTTTCAGGCTGTATTAATTCAGAAACATCAGAGTATACACTTC 1315
RESULT 6
AAH52212
ID AAH52212 standard; cDNA: 1053 BP.
XX AC
XX AAH52212;

PI L1 N, Xiao H, Liu F;
 XX WPI: 2001-183596/19.
 DR P-PSDB: AAB60663.
 XX
 PT Human gene expression regulatory factor related protein and its coded
 sequence -
 XX
 PS Claim 1: Page 18-19; 20pp: Chinese.
 XX
 CC The invention relates to a novel human gene expression regulatory
 CC factor-related protein, hnrf3-s (NGF1-interacting factor, AAB60663),
 CC and cDNA encoding it (AAFS9945). hnrf3-s is expressed in haemopoietic
 CC stem cells. The invention also relates to the preparation of hnrf3-s
 CC proteins and nucleic acids, and the detection of hnrf3-s proteins and
 CC nucleic acids in a sample. The present sequence represents cDNA encoding
 CC hnrf3-s.
 XX
 XX
 SQ Sequence 1398 BP; 365 A; 331 C; 342 G; 360 T; 0 other;
 Query Match 54.58; Score 846; DB 22; Length 1398;
 Best Local Similarity 99.78; Pred. No. 0;
 Matches 1196; Conservative 0; Mismatches 1; Indels 3; Gaps 2;
 QY 128 TCCTGTTTTCACCTGCTGTAAGAGCCCTGAAGTGCACATGAATGAGCATATGTA 187
 DB 119 TCCTGTTTTCACCTGCTGTAAGAGCCCTGAAGTGCACATGAATGAGCATATGTA 178
 QY 188 GTCCCCACGACAGTCCGTTTGTAGATCCCTGATCTGCATTTCTCCCTTCATG 247
 DB 179 GTCCCCACGACAGTCCGTTTGTAGATCCCTGATCTGCATTTCTCCCTTCATG 238
 QY 248 GATTGGAAGGCTCTCCTTCTCCTTGAATGACTTGCATCCCTCCTGTTGCGAGAT 307
 DB 239 GATTGGAAGGCTCTCCTTCTCCTTGAATGACTTGCATCCCTCCTGTTGCGAGAT 298
 QY 308 TGGGACAATGTTGATTAATGTTGTAAGCAAGCCACACATATCTTAATATACCTTTC 367
 DB 299 TGGGACAATGTTGATTAATGTTGTAAGCAAGCCACACATATCTTAATATACCTTTC 358
 QY 368 CTGACCAATGACTGACTGGAAGTGTAGAGAGTGTCTGCAAAAGAAAGGACAGCTC 427
 DB 359 CTGACCAATGACTGACTGGAAGTGTAGAGAGTGTCTGCAAAAGAAAGGACAGCTC 418
 QY 428 ATTCTCTCCACACCTGCTATCTTCCGACCCATGAAGGCA-TAACCTGGAACATG 486
 DB 419 ATTCTCTCCACACCTGCTATCTTCCGACCCATGAAGGCAATTAAGGCAACATG 478
 QY 487 G--AAGGAGCGCTGATCCGGCTCTGAGAACAGAGTGGTATCTACTCTCAT 544
 DB 479 GGAAGGAGCGCTGATCCGGCTCTGAGAACAGAGTGGTATCTACTCTCAT 538
 QY 545 ACAAGCTGATGCTGCGCCCAAGGGCGTCAACAATGTTGGCTAAAGGCTTGAAGT 604
 DB 539 ACAAGCTGATGCTGCGCCCAAGGGCGTCAACAATGTTGGCTAAAGGCTTGAAGT 598
 QY 605 TTAGCTCCAGGCGCCCAATCAATCTTCCAAAGCTCCCACTACCTTAAGAGGAAACAC 664
 DB 599 TTAGCTCCAGGCGCCCAATCAATCTTCCAAAGCTCCCACTACCTTAAGAGGAAACAC 658
 QY 665 CGAGTAGAATTAACGTTAATCAACCAAGACCTGAGCAAAAGTATGATGAGTAA 724
 DB 659 CGAGTAGAATTAACGTTAATCAACCAAGACCTGAGCAAAAGTATGATGAGTAA 718
 QY 725 GGAATGAGCGTGTCTGCTACTCTTTTCTGCTAAGACTGTAATGAGAAACA 784
 DB 719 GGAATGAGCGTGTCTGCTACTCTTTTCTGCTAAGACTGTAATGAGAAACA 778
 QY 785 CGGATTAATGATTAATGATTAATGATTAATGATTAATGATTAATGATTAATGATTA 844
 DB 779 CGGATTAATGATTAATGATTAATGATTAATGATTAATGATTAATGATTAATGATTA 838
 QY 845 AACAAACACTTATACGAAGAGCGAAATTTCTGCTACTGAGAGACCTTGTCTTCTCAT 904

DB 839 AACAAACACTTATACGAAGAGCGAAATTTCTGCTACTGAGAGACCTTGTCTTCTCAT 898
 QY 905 ACTGGAATGGAGCGGTATATGACACTGATGAATCTGTCTCCCTGGCAACCATATGAT 964
 DB 899 ACTGGAATGGAGCGGTATATGACACTGATGAATCTGTCTCCCTGGCAACCATATGAT 958
 QY 965 CGAATTAAGAGACACTTAATCAATTTCTGCTTACGCTTGGGGTGGGAGAAC 1024
 DB 959 CGAATTAAGAGACACTTAATCAATTTCTGCTTACGCTTGGGGTGGGAGAAC 1018
 QY 1025 TTAGAGTCTCAAGTCAAAAGTGTGGCCCTGTGCTGCTGTTGAGGAGAGCTTCTGAG 1084
 DB 1019 TTAGAGTCTCAAGTCAAAAGTGTGGCCCTGTGCTGCTGTTGAGGAGAGCTTCTGAG 1078
 QY 1085 GGTGTTAGAGCTGACCTTTTACCTCAAGGTGATGTCCTCATCATGATCTTGGATGCT 1144
 DB 1079 GGTGTTAGAGCTGACCTTTTACCTCAAGGTGATGTCCTCATCATGATCTTGGATGCT 1138
 QY 1145 GCTTCCCAAGGAATTAATGTCATCTCTGTAACACAGCAACACTGAACGAGCTTCTT 1204
 DB 1139 GCTTCCCAAGGAATTAATGTCATCTCTGTAACACAGCAACACTGAACGAGCTTCTT 1198
 QY 1205 TCTGACCTTCGAGATATGCTGATTCACCTTGGAGATAATATATATCTATCA 1264
 DB 1199 TCTGACCTTCGAGATATGCTGATTCACCTTGGAGATAATATATATCTATCA 1258
 QY 1265 GAGACTGACAGGAGCCCTCTTCAAGGTGATTAATGCAAAATCAAGATTAACATTC 1324
 DB 1259 GAGACTGACAGGAGCCCTCTTCAAGGTGATTAATGCAAAATCAAGATTAACATTC 1318

RESULT 8
 ABL60919
 ID ABL60919 standard; cDNA: 1385 BP.
 XX
 AC ABL60919;
 XX
 DT 23-SEP-2002 (first entry)
 XX
 DE Human protein kinase C 27.17 polypeptide encoding cDNA.
 XX
 KW Human; protein kinase C 27.17; protein metabolism; gene; ss.
 XX
 OS Homo sapiens.
 XX
 PN CNI33335-A.
 XX
 PD 30-JAN-2002.
 XX
 PF 07-JUL-2000; 2000CN-0117049.
 XX
 PR 07-JUL-2000; 2000CN-0117049.
 XX
 PA (SHAN-) SHANGHAI BIODOOR GENE DEV CO LTD.
 XX
 PI Mao Y, Xie Y;
 XX
 DR WPI: 2002-305609/35.
 DR P-PSDB: ABB08182.
 XX
 PT Human protein kinase C 27.17 polypeptide and its encoding
 PT polynucleotide, for treating e.g. protein metabolism disturbance -
 PS Claim 6; Page 25-26 (disclosure); 33pp: Chinese.
 XX
 CC The invention relates to a human protein kinase C 27.17 polypeptide and
 CC its encoding polynucleotide. The polypeptide can be expressed by standard

PR 11-JUL-2000; 2000US-0217496.
 PR 14-JUL-2000; 2000US-0218290.
 PR 26-JUL-2000; 2000US-0220963.
 PR 14-AUG-2000; 2000US-0220964.
 PR 14-AUG-2000; 2000US-0224518.
 PR 14-AUG-2000; 2000US-0224519.
 PR 14-AUG-2000; 2000US-0225213.
 PR 14-AUG-2000; 2000US-0225214.
 PR 14-AUG-2000; 2000US-0225266.
 PR 14-AUG-2000; 2000US-0225267.
 PR 14-AUG-2000; 2000US-0225268.
 PR 14-AUG-2000; 2000US-0225270.
 PR 14-AUG-2000; 2000US-0225447.
 PR 14-AUG-2000; 2000US-0225457.
 PR 14-AUG-2000; 2000US-0225458.
 PR 14-AUG-2000; 2000US-0225459.
 PR 18-AUG-2000; 2000US-0226279.
 PR 22-AUG-2000; 2000US-0226681.
 PR 22-AUG-2000; 2000US-0226686.
 PR 22-AUG-2000; 2000US-0227182.
 PR 23-AUG-2000; 2000US-0227009.
 PR 30-AUG-2000; 2000US-0228924.
 PR 01-SEP-2000; 2000US-0229287.
 PR 01-SEP-2000; 2000US-0229343.
 PR 01-SEP-2000; 2000US-0229344.
 PR 01-SEP-2000; 2000US-0229345.
 PR 05-SEP-2000; 2000US-0229509.
 PR 05-SEP-2000; 2000US-0229513.
 PR 06-SEP-2000; 2000US-0230437.
 PR 06-SEP-2000; 2000US-0230438.
 PR 08-SEP-2000; 2000US-0231242.
 PR 08-SEP-2000; 2000US-0231243.
 PR 08-SEP-2000; 2000US-0231244.
 PR 08-SEP-2000; 2000US-0231413.
 PR 08-SEP-2000; 2000US-0231414.
 PR 08-SEP-2000; 2000US-0232080.
 PR 08-SEP-2000; 2000US-0232081.
 PR 12-SEP-2000; 2000US-0231968.
 PR 14-SEP-2000; 2000US-0232397.
 PR 14-SEP-2000; 2000US-0232398.
 PR 14-SEP-2000; 2000US-0232399.
 PR 14-SEP-2000; 2000US-0232400.
 PR 14-SEP-2000; 2000US-0232401.
 PR 14-SEP-2000; 2000US-0233063.
 PR 14-SEP-2000; 2000US-0233064.
 PR 14-SEP-2000; 2000US-0233065.
 PR 21-SEP-2000; 2000US-0234223.
 PR 21-SEP-2000; 2000US-0234274.
 PR 25-SEP-2000; 2000US-0234997.
 PR 25-SEP-2000; 2000US-0234998.
 PR 26-SEP-2000; 2000US-0235484.
 PR 27-SEP-2000; 2000US-0235634.
 PR 27-SEP-2000; 2000US-0235636.
 PR 29-SEP-2000; 2000US-0236327.
 PR 29-SEP-2000; 2000US-0236367.
 PR 29-SEP-2000; 2000US-0236368.
 PR 29-SEP-2000; 2000US-0236369.
 PR 29-SEP-2000; 2000US-0236370.
 PR 02-OCT-2000; 2000US-0236802.
 PR 02-OCT-2000; 2000US-0237037.
 PR 02-OCT-2000; 2000US-0237038.
 PR 02-OCT-2000; 2000US-0237039.
 PR 02-OCT-2000; 2000US-0237040.
 PR 13-OCT-2000; 2000US-0239935.
 PR 13-OCT-2000; 2000US-0239937.
 PR 20-OCT-2000; 2000US-0240960.
 PR 20-OCT-2000; 2000US-0241221.
 PR 20-OCT-2000; 2000US-0241785.
 PR 20-OCT-2000; 2000US-0241786.
 PR 20-OCT-2000; 2000US-0241787.
 PR 20-OCT-2000; 2000US-0241808.
 PR 20-OCT-2000; 2000US-0241809.
 PR 20-OCT-2000; 2000US-0241826.

PR 01-NOV-2000; 2000US-0244617.
 PR 08-NOV-2000; 2000US-0246474.
 PR 08-NOV-2000; 2000US-0246475.
 PR 08-NOV-2000; 2000US-0246476.
 PR 08-NOV-2000; 2000US-0246477.
 PR 08-NOV-2000; 2000US-0246478.
 PR 08-NOV-2000; 2000US-0246523.
 PR 08-NOV-2000; 2000US-0246524.
 PR 08-NOV-2000; 2000US-0246525.
 PR 08-NOV-2000; 2000US-0246526.
 PR 08-NOV-2000; 2000US-0246527.
 PR 08-NOV-2000; 2000US-0246528.
 PR 08-NOV-2000; 2000US-0246532.
 PR 08-NOV-2000; 2000US-0246609.
 PR 08-NOV-2000; 2000US-0246610.
 PR 08-NOV-2000; 2000US-0246611.
 PR 08-NOV-2000; 2000US-0246613.
 PR 17-NOV-2000; 2000US-0249207.
 PR 17-NOV-2000; 2000US-0249208.
 PR 17-NOV-2000; 2000US-0249209.
 PR 17-NOV-2000; 2000US-0249210.
 PR 17-NOV-2000; 2000US-0249211.
 PR 17-NOV-2000; 2000US-0249212.
 PR 17-NOV-2000; 2000US-0249213.
 PR 17-NOV-2000; 2000US-0249214.
 PR 17-NOV-2000; 2000US-0249215.
 PR 17-NOV-2000; 2000US-0249216.
 PR 17-NOV-2000; 2000US-0249217.
 PR 17-NOV-2000; 2000US-0249218.
 PR 17-NOV-2000; 2000US-0249244.
 PR 17-NOV-2000; 2000US-0249245.
 PR 17-NOV-2000; 2000US-0249264.
 PR 17-NOV-2000; 2000US-0249265.
 PR 17-NOV-2000; 2000US-0249297.
 PR 17-NOV-2000; 2000US-0249299.
 PR 17-NOV-2000; 2000US-0249300.
 PR 01-DEC-2000; 2000US-0250160.
 PR 01-DEC-2000; 2000US-0250391.
 PR 05-DEC-2000; 2000US-0251030.
 PR 05-DEC-2000; 2000US-0251988.
 PR 05-DEC-2000; 2000US-0256719.
 PR 06-DEC-2000; 2000US-0251479.
 PR 08-DEC-2000; 2000US-0251856.
 PR 08-DEC-2000; 2000US-0251868.
 PR 08-DEC-2000; 2000US-0251869.
 PR 08-DEC-2000; 2000US-0251889.
 PR 08-DEC-2000; 2000US-0251990.
 PR 11-DEC-2000; 2000US-0254097.
 PR 05-JAN-2001; 2001US-0239678.
 PA (HDMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Barash SC, Ruben SM.
 XX
 DR WPI: 2001-483426/52.
 XX
 PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
 PT useful for preventing, diagnosing and/or treating cancers and
 PT metastasis -
 XX
 PS Disclosure; SEQ ID NO 33575; 3071pp + Sequence Listing; English.
 XX
 CC AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)
 CC amino acid sequences given in AAM82170 to AAK91921. (I) have cytostatic
 CC activity, and can be used in gene therapy and vaccine production. (I)
 CC proteins and polynucleotides may be used in the prevention, diagnosis and
 CC treatment of diseases associated with inappropriate (I) expression. For
 CC example, they may be used to treat disorders associated with decreased
 CC expression by rectifying mutations or deletions in a patient's genome
 CC that affect the activity of (I) by expressing inactive proteins or to
 CC supplement the patient's own production of (I). Additionally, (I)
 CC polynucleotides may be used to produce the secreted (I), by inserting
 CC the nucleic acids into a host cell and culturing the cell to express the

protein. (I) proteins and polynucleotides may be used to prevent, diagnose and treat immune/haematopoietic-related diseases, especially cancers and cancer metastases of haematopoietic-derived cells. AAK4703 to AAK87694 represent human immune/haematopoietic antigen genomic sequences from the present invention. AAK54942 to AAK54950 and AAK2169 represent sequences used in the exemplification of the present invention.

Sequence 14969 BP; 4016 A; 3069 C; 3042 G; 4842 T; 0 other;

Query Match 26.7%; Score 414; DB 22; Length 14969;
Best Local Similarity 100.0%; Pred. No. 1e-196;
Matches 414; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

OY 187 AGTCCACGACGACGCGGTTGAGATCCCTGATCCGATCTCCCTCTTCAT 246
DB 2546 AGTCCACGACGACGCGGTTGAGATCCCTGATCCGATCTCCCTCTTCAT 2605
OY 247 GGATTTGAGAGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 306
DB 2606 GGATTTGAGAGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 2665
OY 307 TTGGGACAAATGTTGATTTACTGCTGGAACCAAGCCACATCTGTAATACACTT 366
DB 2666 TTGGGACAAATGTTGATTTACTGCTGGAACCAAGCCACATCTGTAATACACTT 2725
OY 367 CCTGACCAATGACCTGACTGAGAAAGTATGAGAGAGGCTGCAAAAAGAGGACACT 426
DB 2726 CCTGACCAATGACCTGACTGAGAAAGTATGAGAGAGGCTGCAAAAAGAGGACACT 2785
OY 427 CATCTCTCTACCAATCCGCTATCTTCCGACCCATGAAAGGCAATACCTGGAACATG 486
DB 2786 CATCTCTCTACCAATCCGCTATCTTCCGACCCATGAAAGGCAATACCTGGAACATG 2845
OY 487 GAAGAGCGCGCTGCTGATCCGGGCTCTGGAACAGAGTCCGATCTCTCTCTCTCTCT 546
DB 2846 GAAGAGCGCGCTGCTGATCCGGGCTCTGGAACAGAGTCCGATCTCTCTCTCTCTCT 2905
OY 547 AGCTATGATGCTCTGCGCCGAGGCGTCAACACATGCTGCTAAAGGCTTTGG 600
DB 2906 AGCTATGATGCTCTGCGCCGAGGCGTCAACACATGCTGCTAAAGGCTTTGG 2959
```

RESULT 12

AA85172/c

ID AA85172 standard; cDNA; 1686 BP.

XX AA85172;

XX 13-FEB-2002 (first entry)

DE DNA encoding novel human diagnostic protein #20976.

XX Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder; ss.

XX Homo sapiens.

XX WO200175067-A2.

XX 11-OCT-2001.

XX 30-MAR-2001; 2001WO-US08631.

XX 31-MAR-2000; 2000US-0540217.

XX 23-AUG-2000; 2000US-0649167.

XX (HXSE-) HXSEQ INC.

XX Drmanac RF, Liu C, Tang YT;

XX WPI; 2001-639362/73.

XX P-PSDB; ABG20985.

XX

PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders, or other traits and to assess
PT biodiversity

PS Claim 1; SEQ ID No 20976; 103pp; English.

CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. AA564197-AA594564 represent novel human
CC diagnostic coding sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.

SO Sequence 1686 BP; 445 A; 397 C; 391 G; 452 T; 1 other;

Query Match 22.0%; Score 341; DB 23; Length 1686;
Best Local Similarity 100.0%; Pred. No. 3.7e-160;
Matches 341; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

OY 729 TTGAGCGTGTCTCTGCTCACTCTTTCTGCTAGACATGTAATGAGAACAAACGGA 788
DB 871 TTGAGCGTGTCTCTGCTCACTCTTTCTGCTAGACATGTAATGAGAACAAACGGA 812
OY 789 TTAATCTAATTTGTAATCTAGAAAGCTTTGATGACAGGTGTGATTTCTTTCCGGAACA 848
DB 811 TTAATCTAATTTGTAATCTAGAAAGCTTTGATGACAGGTGTGATTTCTTTCCGGAACA 872
OY 849 AACACCTTATCAGAGAGCGGAATCTGTCTACCTGAGAACGCTTGTCTACATCTG 908
DB 751 AACACCTTATCAGAGAGCGGAATCTGTCTACCTGAGAACGCTTGTCTACATCTG 962
OY 909 GAATGGAGCGGTTATGACACATGATGATCTGTCTCCCTGGCAACATGATGATCGAA 968
DB 691 GAATGGAGCGGTTATGACACATGATGATCTGTCTCCCTGGCAACATGATGATCGAA 632
OY 969 TAAAAAGACACCTAAACATATCTCATTTCCGCTTGGGCTTGGGAGAACCTTAG 1028
DB 631 TAAAAAGACACCTAAACATATCTCATTTCCGCTTGGGCTTGGGAGAACCTTAG 572
OY 1029 AGTCTCAAGTCNAAGTCGTGGCGCTGTGCTGCTTGGG 1069
DB 571 AGTCTCAAGTCNAAGTCGTGGCGCTGTGCTGCTTGGG 531
```

RESULT 13

AA15105

ID AA15105 standard; cDNA; 514 BP.

XX AA15105;

XX 07-DEC-2001 (first entry)

XX Human breast cancer expressed polynucleotide 7562.

XX Human; breast cancer; cell marker; cytostatic; ss.

XX Homo sapiens.

[illegible]

PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239335.
PR 13-OCT-2000; 2000US-0239337.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.

PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Rosen CA, Barash SC, Ruben SM;
PI WPI, 2001-483426/52.
XX P-PSDB; AAM90790.
DR Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PS metastasis -
XX Claim 1; SEQ ID NO 8631; 3071pp + Sequence Listing: English.
XX AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytosstatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patient's own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/hematopoietic-related diseases, especially
CC cancers and cancer metastases of hematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/hematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
XX Sequence 463 BP; 97 A; 103 C; 132 G; 126 T; 5 other;
Query Match 14.4%; Score 223; DB 22; Length 463;
Best Local Similarity 99.6%; Pred. No. 4.5e-101;
Matches 273; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 GTGATTGTTATCTTGTCCTCAGAGACAGACAGAGAGATTGGTTCAGAAACTGC 60
DB 53 GTGATTGTTATCTTGTCCTCAGAGACAGACAGAGAGATTGGTTCAGAAACTGC 112
QY 61 CTTGCCGACACAGACAGACAGACAGACAGACAGAGAGAGAGAGAGAGAGAGAG 120
DB 113 CTTGCCGACACAGACAGACAGACAGACAGACAGAGAGAGAGAGAGAGAGAGAG 172
QY 121 CTGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG 180
DB 173 CTGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG 232
QY 181 TAGATGAGTCCCGACAGACAGACAGACAGACAGACAGACAGACAGACAGACAG 240
DB 233 TAGATGAGTCCCGACAGACAGACAGACAGACAGACAGACAGACAGACAGACAG 292
QY 241 CTTGATGATTTGAAGGCTCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 274
DB 293 CTTGATGATTTGAAGGCTCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 326
RESULT 15
ABA46423/C
ID ABA46423 standard; DNA; 465 BP.
XX ABA46423;
AC
XX
DT 01-FEB-2002 (first entry)
DE Human breast cell single exon nucleic acid probe #5118.
XX

